Sarah Fink, an associate in Goodwin’s IP Litigation Department, focuses her practice on patent and regulatory matters unique to the pharmaceutical industry, including the interplay between patent and FDA regulatory goals. She primarily represents clients in proceedings before the U.S. Patent and Trademark Office's Patent Trial and Appeal Board, including in inter partes review and post-grant review. Ms. Fink also provides patent opinions and related client counseling, including counseling regarding the “Patent Dance” under the Biologics Price Competition and Innovation Act, Orange Book issues, labeling, and patent notice letters. Ms. Fink reviews SEC filings of FDA-regulated companies and conducts due diligence as part of mergers and acquisitions and initial public offerings.

She has experience litigating complex patent cases before the United States district courts and the U.S. International Trade Commission.

Ms. Fink is an active member of Goodwin’s PTAB practice group, and is co-founder and co-author of a Goodwin publication The PTAB Trial Tracker, which provides updates about PTAB, district court, and Federal Circuit decisions that impact post-grant review proceedings. Ms. Fink is a regular contributor to the firm’s Big Molecule Watch blog, and her posts are primarily directed to IPR proceedings concerning patents on biologics products and their manufacturing processes. She also upkeeps the IPR Tracker page on the Big Molecule Watch blog.

Ms. Fink has an active pro bono practice, representing parents of children with special needs and helping them to secure appropriate education services for their children.

Areas of Practice
Domaines D’Expertise





Ms. Fink has advised numerous clients on their post-grant review and litigation strategies. In addition to these confidential matters, Ms. Fink routinely represents clients at the PTAB. Her recent representations include the following:

  • Representation of a branded drug company in a litigation pending at the District of Delaware and related post-grant proceedings before the PTAB concerning the company’s multiple sclerosis drug.
  • Representation of a generic drug company in a litigation before the District of New Jersey and related post-grant proceedings before the PTAB concerning the client’s proposed generic version of an anti-inflammatory eye-drop formulation. The dispute resulted in a successful settlement for the client.
  • Representation of a pharmaceutical company in post-grant proceedings before the PTAB concerning a proposed biosimilar to an anti-rheumatic branded biologic product.


Ms. Fink was the 2012 recipient of the Jan Jancin Award, an annual award by the American Intellectual Property Association that recognizes an outstanding law student who has excelled in the study of IP law.

In The News









J.D., 2012
St. John's University School of Law
(summa cum laude)
B.E., Chemical Engineering, 2002
The Cooper Union



New York
U.S. Patent and Trademark Office (USPTO)
Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique